CTLA4 and melanoma: Intratumoral expression of the NK cell marker CD56 has been shown to correlate with clinical response to ipilimumab in patients with melanoma, suggesting that anti-CTLA-4-induced Treg depletion is mediated at least in part by NK cells [30].